利于心血管的类药物效应的他类药物
1Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Québec, Canada. davignj@ircm.qc.ca
Circulation
|June 17, 2004
概括
类他类药物提供了除了通过有益的类作用降低胆固醇之外的心血管保护. 了解这些额外的药物作用是优化心脏病预防他类药物治疗的关键.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 药物发现 药物发现 药物发现
背景情况:
- 类药物效应是超出其主要治疗标的作用.
- 这些影响可以是有益的,中性的或有害的.
- HMG-CoA减小酶抑制剂 (他类药物) 显示出显著的有益类作用.
研究的目的:
- 为了探索他类药物的类效应.
- 了解这些影响如何促进心血管保护.
- 为了优化他类药物的临床使用.
主要方法:
- 关于他类药物的药理学研究的文献综述.
- 分析类作用背后的机制.
- 类效应与心血管结果的相关性.
主要成果:
- 类药物可以改善内皮功能和氧化的生物可用性.
- 它们具有抗氧化和抗炎性质.
- 类药物稳定动脉样硬化斑块,降低心血管疾病的风险.
结论:
- 类他类药物的性作用补充了它们的降脂作用.
- 这些综合作用提供了强大的心血管保护.
- 进一步了解类型学可以改进他类药物治疗策略.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
Cholesterol: Significance and Regulation
2.0K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.0K
Atherosclerosis III: Management
726
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
726


